Replies to post #14832 on Algernon Pharmaceuticals Inc (AGNPF)

[Uncle buckshot]

I doubt that will ever happen. I would imagine fda got back to AP weeks ago with positive feedback
But none of that is in the cards for us.
But just got word we are at 70% enrolment for CC.
So 14 of 20. I believe we were at 11 in early April

Got to love the quote from CM


We are very pleased with the enrolment rate.

Lmao. I think we all have underestimated the true value of our CEO at AP

[tcm55]

AGN had good Il-6 and low O-2 significant data. BS or is that real?
The decision to not go forward with Phase 3 because of costs and a waning COVID pandemic seems almost logical but to say data was not strong and just DROP Ifenprodil until after IPF/CC data???

Another stock is running well on weaker data for IL1 and IL-6, but they followed patients to 60 days to get something to present. (Mostly fluff, IMO) 195 patients and AGN treated 165.
Yep. screwed us hard with no Real explanation - no comment on what went right - no direction - and putting a snuffer on Ifenprodil by saying weak data??? WTF???

I have avoided bashing, butt, WTF? Inept? Stupid?...GLTA...

https://www.globenewswire.com/en/news-release/2021/05/12/2228023/0/en/Algernon-Pharmaceuticals-Announces-Ifenprodil-Reduced-Interleukin-6-in-Phase-2b-3-COVID-Study.html

https://www.globenewswire.com/en/news-release/2021/03/31/2202350/0/en/Algernon-Pharmaceuticals-Announces-Topline-Data-From-its-Phase-2b-3-COVID-19-Trial-of-Ifenprodil.html

[shell3]

Threw some coin @ your Post

PlusOne’d you — smoki